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I.  INTRODUCTION 
 
Perfluorooctanoic acid (PFOA) is a synthetic organic chemical that consists of an 
8 carbon alkyl chain with a terminal carboxyl group in which the carbon-hydrogen bonds 
have been replaced with carbon-fluorine bonds except at the terminal carboxyl end.  This 
perfluoralkyl carboxylate is a contemporary synthetic chemical that does not occur 
naturally in the environment [1] and has only seen widespread use within the last 50 
years.     Ammonium Perfluorooctanoate (APFO) is the ammonium salt derivative of 
PFOA and is used in the manufacturing process and readily disassociates into PFOA in 
the human body and environment.  The data on APFO/PFOA can be used 
interchangeably since, in the presence of water, APFO readily dissociates into the PFOA 
anion [2]. 
PFOA is used in the manufacture of fluoropolymers and fluoroelastomers and is 
present as a component of some of the top-antireflective coating materials in use today.  
Fluoropolymers have properties that are useful in the manufacturing and textile industry 
such as fire resistance and their ability to repel oil, stain, grease and water which makes 
them ideal for creating a non-stick surface for cookware and protective coatings on 
clothing and carpeting and are also valuable to the aerospace industry as well.  
Fluoroelastomers are a family of synthetic rubbers that can be repeatedly stretched and 
still return to their original shape, such as Viton.  Sinclair et al. found measurable PFOA 
released from several brands of nonstick cookware when heated which suggests that 
residual PFOA from the manufacturing process may remain on the surface and can be 
off-gassed when heated at normal cooking temperatures. This study also found that 
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PFOA was present in the vapors released from prepackaged microwave popcorn bags that 
are impregnated with PFOA to improve oil and fire resistance during microwaving. [3]  
Since there has been recent progress in understanding the developmental, tumorigenic 
and other adverse effects seen in laboratory animals exposed to PFOA, the purpose of 
this review is to provide an overview of the tumorigenic modes of action of PFOA that 
result in the tumor triad seen in rodents and to determine the relevance of these studies to 
human risk. 
 
A.  Environmental Persistence 
The hydrogen-fluorine bonds found in PFOA are extremely stable and as a result 
PFOA is resistant to hydrolysis, photolysis, biodegradation, and metabolism leading to a 
high degree of environmental persistence and bioaccumulation.  In January 2006, the 
Environmental Protection Agency (EPA) initiated the 2010/15 PFOA Stewardship 
Program in which the eight major companies in the industry committed voluntarily to 
reduce facility emissions and product content of PFOA and related chemicals on a global 
basis by 95 percent no later than 2010, and to work toward eliminating emissions and 
product content of these chemicals by 2015. 
 
B.  Environmental Presence 
The environmental persistence of PFOA has culminated in the ubiquitous 
presence of PFOA in the environment with bioaccumulation in many species worldwide, 
including humans.  We will discuss the results of recent studies that have shown the 
presence of PFOA in human, wildlife and the environment. 
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1)  PFOA in Humans  
 
Recent studies of human populations in the United Sates have demonstrated the 
presence of PFOA in similar concentrations in the serum of children, adults and the 
elderly in the general population as well as in higher concentrations in individuals that 
were occupationally exposed to PFOA as summarized in Table 1.1.  A study by Olsen et 
al. of 645 serum samples collected in 2001 from adults in the cities of Los Angeles, 
Boston, Minneapolis-St Paul, Charlotte, Portland, and Hagerstown found PFOA levels in 
serum that ranged from 1.4 ng/ml to 56.1 ng/ml with a geometric mean for all samples of  
4.6 ng/ml [4].  In this study the geometric mean PFOA levels were 4.9 ng/ml for males 
and 4.2 ng/ml for females.  Serum collected in 2001 from 238 elderly adults (age 65-96 
years) in Seattle also demonstrated PFOA concentrations in the range of 1.4 ng/ml to 16.7 
ng/ml with a geometric mean of all samples of 4.2 ng/ml.  Olsen et al. [5] also measured 
PFOA in serum collected from 598 children ages 2-12 at concentrations ranging from 1.9 
ng/ml- 56.1 ng/ml in samples collected in 1994 and 1995.  The geometric mean for all 
participants was 4.9 ng/ml with a geometric mean of 5.2 ng/ml for males and 4.7 ng/ml 
for females.  In a 2000 study by Olsen et al. of PFOA levels in the serum of 
occupationally exposed workers, Olsen determined that PFOA concentrations were over 
300 times higher in the serum of workers at a 3M Decatur Alabama plant than that of the 
general population [6].  Olsen reported a geometric mean of 1130 ng/ml from a sample of 
263 Decatur employees.  Serum samples collected from 2,094 members of the general 
US population in 2003-2004 for the National Health and Nutrition Examination Survey 
(NHANES) also indicated the presence of PFOA at a mean concentration of 3.9 ng/ml.  
This is a decrease from the mean PFOA concentration of 5.0 ng/ml found in the serum of 
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1562 participants in the 1999-2000 NHANES.  It is also important to note that PFOA was 
quantifiable in 99.7% of the U.S. population tested in this study [7].   
Table 1.1    
Summary of Geometric Mean and Range of PFOA Serum Concentrations in United States 
Populations 
Year 
Samples 
Taken 
Number Location Demographic 
PFOA 
Mean 
(ng/ml) 
Range 
(ng/ml) Reference 
2001 125 Los Angeles, CA 
Adult                  
General 
Population 
4.1 2.1-34.1 [4] 
2001 109 Boston, Ma 
Adult                  
General 
Population 
5.4 1.5-13.9 [4] 
2001 100 Mpls-St.Paul, MN 
Adult                  
General 
Population 
4.5 1.9-20.0 [4] 
2001 96 Charlotte, NC 
Adult                 
General 
Population 
6.3 2.1-29.0 [4] 
2001 107 Portland, OR 
Adult                  
General 
Population 
3.6 2.1-16.7 [4] 
2001 108 Hagerstown, MD 
Adult                  
General 
Population 
4.2 2.1-52.3 [4] 
2001 238 Seattle, WA 
Elderly Adult  
General 
Population 
4.2 1.4-16.7 [8] 
1994-
1995 598 23 US States 
Children             
General 
Population 
4.9 1.9-56.1 [5] 
2000 263 Decatur, AL 
Adult with          
Occupational 
Exposure 
1,130 40-12,700 [6] 
1999-
2000 1562 
US 
Population 
Adult                  
General 
Population 
5.0 *4.7-5.7 [7] 
2003-
2004 2094 
US 
Population 
Adult                  
General 
Population 
3.9 *3.6-4.3 [7] 
*95th percentile confidence interval range. 
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The global presence of PFOAs in the human population has been evidenced by 
detection of PFOA in the blood of human adults in Columbia, Poland, Belgium, India, 
Korea, Japan, Sweden, China, Australia, Germany and Spain [9-14].  Results found in a 
recent study by Jin et al. on the serum levels taken in 1987, 1990, 1999 and 2002 from 
students, staff and faculty members at China Medical University in Shenyang China are 
indicative of the exposure to PFOA in the general population that is not occupationally 
exposed to PFOA [10].  Table 2.1 summarizes the significant increase of PFOA levels 
seen in the Shenyang China general population from 1987-2002. 
 
Table 1.2   
Summary of Serum PFOA Concentrations (ng/ml) in Shenyang China Population 
 
The marked increase of PFOA levels present in the blood of occupational exposed 
workers in the United States was reproduced in a study of exposed workers in Antwerp 
Belgium.  A study performed in 2000 by Olsen et al. [4] found the geometric mean level 
of PFOA in 255 occupationally exposed Antwerp workers to be 440 ng/ml with a range 
of 40- 6,240 ng/ml as compared to the range of 4.5-27 ng/ml found in a sample of 20 
members of the general Belgium population [11]. 
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2)  PFOA in Wildlife 
 The environmental persistence of PFOA and its global presence has triggered 
studies for detection of the compound in several species of wildlife across the globe.  
PFOA has been found in the sera of captive wildlife species Bengal tigers (Panthera tigris 
tigris) and African lions (Panthera leo Linnaeus) from Harbin Wildlife Park, Heilongjiang 
Province, in China [15].  PFOA was found in 175 samples of liver and blood of bluefin 
tuna (Thunnus thynnus), swordfish (Xiphias gladius), common cormorants 
(Phalacrocorax carbo), bottlenose dolphins (Tursiops truncatus), striped dolphins 
(Stenella coeruleoalba), common dolphins (Delphinus delphi), fin whales (Balenoptera 
physalus), and long- finned pilot whales (Globicephala melas) from the Italian coast of 
the Mediterranean Sea and in livers of ringed seals (Phoca hispida), gray seals 
(Halichoerus grypus), white-tailed sea eagles (Haliaeetus albicilla), in Atlantic salmon 
(Salmo salar) from coastal areas of the Baltic Sea [16].  PFOA has been found in the 
plasma of 73 loggerhead sea turtles (Caretta caretta) and 6 Kemp's ridley sea turtles 
(Lepidochelys kempii) captured from inshore waters of Core Sound, North Carolina 
(NC), and offshore waters of South Carolina, Georgia, and Florida. [17].  PFOA has even 
been detected in the serum of the giant panda and the red panda from zoos and animal 
parks from six provinces in China and has also been detected in all specimens of 
European Beaver's (Castor fiber) liver, in whole blood of Cod (Gadus morhua), Velvet 
Scoter (Melanitta fusca), Eider Duck (Sommateria mollisima), Long-tailed Duck 
(Clangula hyemalis), Razorbill (Alca torda), Red-throated Diver (Gavia stellata) sampled 
in Poland [18, 19].    PFOA has even been shown to be present in increasing levels in 
East Greenland as demonstrated by a study of a subsample of 128 subadult (3-5 years) 
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polar bears (Ursus maritimus) from 19 sampling years within the period 1984-2006 in 
which median concentrations showed a significant annual increase of 2.3%. [20] 
 
3)  PFOA in the Environment 
 
PFOA contamination has been found in fresh water bodies of the European 
region.  The PFOA levels concentrations were measured in samples of freshwater from 
several countries including Germany, Italy, Norway, and Sweden and were found to be in 
the range of <0.65–57 ng/L with approximately 75% of the data falling between  the 
range of non-detectable and 8 ng/L.   [21-25].   
Levels of PFOA contamination have been found in the surface fresh water of the 
German Ruhr area and of the river Moehne and selected contaminated tributaries where 
PFOA concentrations up to 3640 and 33,900 ng/L, respectively were found.   Saito [26], 
Tanaka [22] and So [27] reported that several surface fresh water bodies in Asia, from 
samples collected in China, Japan and other Asian areas, had PFOA concentrations 
mostly in the range of 0.10–41.60 ng/L, with peaks up to 456 ng/L.  In studies of North 
American fresh water A number of studies of surface water of the Great Lakes region 
reported PFOA concentrations of <2–59 ng/L [28-30].   
Atmospheric Levels of PFOA in Europe were measured in 2005 by de Voogt 
[24]. The PFOA levels varied from 0.226–0.828 ng/m3 in March 2005 and from 0.006–
0.222 ng/m3 in November.  Atmospheric PFOA levels, measured in the towns of  
Oyamazaki  and Morioka located in Kyoto Japan, and were found to be in the range of 
0.00159–0.919 ng/m3 with a Geometric mean of 0.2627 ng/m3 found in Oyamazaki and a 
geometric mean of 0.0020 ng/m3 found in Morioka [31, 32].  High levels of PFOA were 
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found in samples taken over a 10-week period by the fence of a fluoropolymer 
manufacturing facility in the United States where Barton [33] reported PFOA 
concentrations up to 900 ng/m3. 
PFOA is also found in the home.  House dust from homes (n = 102) and day care 
centers (n = 10) in Ohio and North Carolina in 2000-2001 were sampled and PFOA was 
measured at median concentrations of 142 ng/g of dust, with a maximum PFOA 
concentration of 1960 ng/g [34].  PFOA was found in dust samples that were taken from 
67 houses in Canada at levels in the range of 1.15–1234 ng/g of dust with a mean 
concentration of 106 ng/g [35].  Moriwaki [36] reported detection of PFOA in the indoor 
dust of Japanese houses at levels of 69–3700 ng/g with a  mean level of 380 ng/g.  
 
C.  Chemical and Physical Properties 
The following are the chemical and physical properties of PFOA: 
Molecular Formula:  C8-H-F15-O2  
Chemical Structure: 
 
  
 
Molecular Weight: 414.09 [37] 
Boiling Point: 189 deg C [38] 
Melting Point: 52-54 deg C [38] 
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Density/Specific Gravity: 1.792 g/ml @ 20 oC [38]  
Dissociation Constants: pKa = 2.80 [39] 
Vapor Pressure: 0.15 mm Hg @ 25 oC [40] 
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II. TOXICITY IN ANIMALS 
 
A.  Acute Toxicity  
Olson and Anderson [41] calculated the 30 day LD50 of a single IP injected dose 
of PFOA to be 189 mg/kg (175-208 mg/kg).  All rats treated with doses of PFOA of 175 
mg/kg or greater died within 5 days of exposure.  The LD50 for oral exposure was 
determined to be 680 mg/kg for male CD rats and 430 mg/kg for female CD rats by Dean 
and Jessup [42].  Glaza [43] determined that the LD50 for female Spraque-Dawley rats to 
be in the range of 250-500 mg/kg and the LD 50 for male Spraque-Dawley rats to be 
greater than 500 mg/kg which supports the results from Dean and Jessup.  The LD 50 
from the acute toxicity studies performed in rodents are summarized in Table 2.1 below. 
Table 2.1 
Summary of PFOA LD50 values 
 
 
 
Species Dose Exposure Route Reference 
Male Fischer rats LD 50/30day= 189 mg/kg IP [41] 
Male CD rats LD 50= 680 mg/kg Oral [42] 
Female CD rats LD 50= 430 mg/kg Oral [42] 
Male Spraque-Dawley rats LD 50= >500 mg/kg Oral [43] 
Female Spraque-Dawley rats LD 50=  250-500 mg/kg Oral [43] 
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B.  Subchronic Toxicity 
Subchronic toxicity studies were performed by Goldenthal [44] in rhesus 
monkeys (2 of each sex per group) at doses of 0, 3, 10, 30 and 100 mg/kg per day by 
gavage in 0.5% Methocel 7 for a period of 90 days.  Table 2.2 contains a summary of the 
PFOA levels found in the surviving animal’s serum and liver tissue at sacrifice.   
 
Table 2.2 
 Summary of the PFOA levels found in surviving monkeys at sacrifice 
 
All animals in the 100 mg/kg per day died during the study with the first death 
occurring during the second week, with death occurring in all animals by the fifth week.  
One male from the 30 mg/kg per day group died during week 7 and two females from 
this group also died during weeks 12 and 13.  All the animals that died during the study 
exhibited marked diffuse lipid depletion in the adrenal glands, slight to moderate bone 
marrow hypoplasia and atrophy of the lymphoid follicles in the lymph nodes.  Of the 
animals that survived until sacrifice, one male in the 30 mg/kg per day group exhibited 
similar marked diffuse lipid depletion in the adrenal glands, slight to moderate bone 
Daily 
Dose 
(mg/kg) 
Serum PFOA (µg/ml) Liver (µg/ml) 
Total PFOA Liver 
(µg) 
Male Female Male Female Male Female 
0 ND 1 0.05 0.07 3 5 
3 53 65 3 7 250 350 
3 48 50 ND ND ND ND 
10 45 79 9 ND 600 ND 
10 71 71 ND 10 ND 750 
30 145 Dead 61 Dead 4000 Dead 
30 Dead Dead Dead Dead Dead Dead 
100 Dead Dead Dead Dead Dead Dead 
100 Dead Dead Dead Dead Dead Dead 
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marrow hypoplasia and atrophy of the lymphoid follicles in the lymph nodes that was 
present in the animals that died during the study.  The absolute and relative weight of the 
hearts and the absolute brain weight were significantly decreased in females from the 10 
mg/kg per day group.  It was also noted that the mean weight of the pituitary in males 
from the 3 mg/kg per day group was significantly increased.  
Two subchronic toxicity studies were performed in male cynomolgus monkeys by 
Thomford in 2001 [45, 46]. The first was a 6 month study in which male cynomolgus 
monkeys were administered 0, 2 or 20 mg/kg per day orally via a capsule.  All animals 
survived until sacrifice and there were no adverse effects noted in either the gross or 
clinical studies.  This study was then followed by a 26 week study in which male 
cynomolgus monkeys were given 0, 3, 10 or 30 mg/kg doses per day orally via a capsule.  
Dosing was discontinued at day 11 because of statistically significant weight loss, 
decreased food consumption and decreased feces production in the 30 mg/kg per day 
group.  Treatment of this group was then resumed on day 22 at a 20 mg/kg per day dose.   
At sacrifice significant increases were noted in the mean absolute liver weights and the 
liver to body weight percentages in all groups receiving PFOA.  Thyroid hormones were 
also found to be decreased beginning on day 35 in the 10 and 30/20 mg/kg per day 
groups.  This study demonstrated a lowest-observed-adverse-effect-level of 3 mg/kg per 
day. 
A 28 day study by was conducted by Christopher and Marias [47] using ChR-CD 
mice (5/sex per group) administered a daily dietary dose of APFO (the ammonium salt of 
PFOA used in fluoropolymer manufacturing) ranging from 0 to 30,000 ppm.   All 
animals in the 1000 ppm and higher group died within the first 9 days of treatment, while 
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death of all the animals with the exception of one male in the 300 ppm occurred within 
26 days of treatment.  There was a dose-related reduction in the mean body weight of all 
the treated animals.  Liver weights were increased in mice receiving a dose of 30 ppm or 
greater.  Morphological changes in the livers of all treated animals were observed 
including changes, enlargement and/or discoloration of 1 or more lobes of the liver, a 
diffuse cytoplasmic enlargement of hepatocytes throughout the liver, with a random 
distribution of cytoplasmic lipid vacuoles of variable sizes.   
The results of a second 28-day study using the same APFO doses as Christopher 
and Marias were described in a report by Metrick and Marias [48].  All animals receiving 
a dose that was greater than 10,000 ppm died before the end of the first week of the study 
with morphological changes noted in the livers of all the animals who received APFO.  
The morphological changes in the liver noted in the study consisted of panlobular diffuse 
hypertrophy of the hepatocytes with accompanying focal to multifocal cytoplasmic lipid 
vacuoles.  
A 28-day study of the toxicological effects of oral exposure to PFOA and 
Perfluorooctane Sulfonate (PFOS) on male Spraque-Dawley rats by gavage has also been 
performed [49]. Cui used 5 groups of 10 animals per group with the control group 
receiving no perfluorochemicals (PFCs) and the remaining group receiving doses of 5 
mg/kg per day PFOA, 20 mg/kg per day of PFOA, 5 mg/kg per day PFOS and the final 
group received a dose of 20 mg/kg per day of PFOS.  Histological changes in the 
hepatocytes were observed in all exposed groups.  These changes included fatty 
degeneration, angiectasis in the central vein, congestion in the hepatic sinusoid, 
acidophilic lesions, focal hemorrhage with necrosis, cytoplasmic vaculation and hepatic 
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enlargement with inflammatory cellular infiltration.  A biodistribution assay was 
performed to measure the PFOA concentrations in the target organs and the tissue 
concentrations were found to be in the order of kidney>liver>lung>heart>testicle>spleen 
and brain. 
 
C.  Mutagenicity 
There is conflicting evidence on the genotoxic effects of PFOA.  Several studies 
conducted for the United States Environmental Protection Agencies by an independent 
laboratory concluded that PFOA and APFO did not induce mutations with or without 
metabolic activation in AMES tests, in human lymphocytes or in Chinese Hamster Ovary 
(CHO) cells [50, 51].  The same laboratory also tested the in-vivo mutagenic properties 
of APFO using micronucleus studies on the bone marrow of mice [52, 53] with negative 
results.  Other studies have found that APFO was able to induce both chromosomal 
aberrations and polyploidy with the presence of metabolic activation in human 
lymphocytes [54, 55]. A recent study by Yao et al. [56] using human the hepatoma cell 
line HepG2 found a significant increase in the tail moment in the single cell gel 
electrophoresis assay in HepG2 cells exposed to PFOA which indicates that PFOA was 
able to induce DNA strand breaks in HepG2 cells.  Yao also found PFOA induced a 
dose-dependent increase in the frequency that a micronucleus was found in binucleated 
HepG2 cells, which indicates that chromosome breaks occurred in HepG2 cells after 
PFOA treatment.  Shabalina et al. [57] found DNA breaks in HepG2 cells exposed to 
PFOA  using the TUNEL procedure and propidium iodide staining of cellular DNA. 
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Although there are conflicting evidence, PFOA has been found to produce a genotoxic 
effect on human cells in some studies.  
 
D.  Carcinogenicity 
Carcinogenicity studies of PFOA in rodents demonstrated that PFOA induced a 
tumor triad which consists of liver adenomas, Leydig cell adenomas and pancreatic 
acinar cell tumors in male Spraque-Dawley rats.   
Sibinski [58] performed a 2 year study of Spraque-Dawley rats exposed to APFO 
in their diet.  Groups of 50 animals from each sex consumed feed containing 0, 30 or 300 
ppm APFO; this corresponded to a mean APFO daily dose of 0.0, 1.3 and 14.2 mg/kg in 
the males and 0.0, 1.6 and 16.1 mg/kg per day in females.  The animals were observed 
daily with body weights and food consumption recorded weekly for the first six months 
and then bi-weekly for the remainder of the study.   
An interim 1 year study was also performed using groups of 15 additional rats per 
sex fed 0 or 300 ppm APFO with the animals sacrificed at 1 year and the weights of the 
kidney, liver, testes, adrenal gland and spleen recorded.  Pathological examinations which 
included hematology, serum chemistry and urinalysis were performed on samples from 
15 rodents from each group at 3, 6, 12, 18 and 24 months.  Post mortem observations 
were recorded on all animals that died during the study and those that were sacrificed at 
the 1 year interim and 2 year study end.  At the 2 year sacrifice, the organs were weighed 
for 15 randomly selected animals per sex in all remaining rats in each group.   On gross 
examination, lesions in the liver, testis and ovary were noted.   
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At the 1 year sacrifice liver hepatomegalocytosis was present in 80% of males 
consuming feed containing 300 ppm APFO with no hepatomegalocytosis seen in the 
control group.  Portal mononuclear cell infiltration was also present in 87% of the 300 
ppm APFO dosed male animals versus 47% of the control male animals and 
hepatocellular necrosis was evident in 40% of the 300 ppm APFO male animals with no 
hepatocellular necrosis observed in the control group.   Testicular masses were also 
discovered in 40% of the 300 ppm dosed group at the 1 year sacrifice with no testicular 
masses observed in the control group.  
At the 2 year sacrifice megalocytosis was present in 12% of the male rats 
consuming feed containing APFO at a concentration of 30 ppm and 80% of the males 
consuming feed with a APFO concentration of 300 ppm.  Megalocytosis was also 
observed in and 2% of the female rats consuming feed containing APFO at a 
concentration of 30 ppm and in 16% of the females that consumed feed with a APFO 
concentration of 300 ppm. There was no megalocytosis observed in either the male or 
female control groups.  It was also noted that hepatic cystoid degeneration was observed 
in 14% and 56% of the 30 ppm and 300 ppm male groups with only 8% observed in the 
control group.  At the 2 year sacrifice a significant increase in the incidence of testicular 
Leydig cell adenomas (LCT) was reported in the high dose group which was present in 
14% of the test animals.  4% of the low dose group also developed LCT with no LCT 
observed in the control group.  Historically, LCT have been observed in 0.82% of control 
animals in 2-year old Spraque-Dawley rats used in carcinogenicity studies [59].  The 
effects noted in this study are summarized in Table 2.3. 
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Table 2.3 
Summary of the Effects of APFO Exposure in Male Rats  
 
Observations 
Incidence   
Control Rats    
(0 ppm APFO) 
Incidence 
Treated Rats     
(30 ppm APFO) 
Frequency  
Treated Rats     
(300 ppm APFO) 
1 Year Sacrifice Male Rats 
Liver 
hepatomegalocytosis  NONE  N/A* 80%  
Portal mononuclear 
cell infiltration 47%  N/A* 87%  
Hepatocellular 
necrosis  NONE  N/A* 40%  
Testicular masses NONE N/A* 40% 
2 Year Sacrifice Male Rats 
Liver 
hepatomegalocytosis NONE 12% 80% 
Hepatic cystoid 
degeneration 8% 14% 56% 
Testicular Leydig 
Cell Adenomas NONE 4% 14% 
* Only rats treated with 0 and 300 PPM APFO were sacrificed at 1 year. 
 
Biegel et al. [60] performed a 2-year study in which APFO was introduced into 
the diet of male CD rats.  The study was conducted using feed containing 300 ppm 
APFO.  Increased relative liver weights and hepatic beta-oxidation activity were observed 
in the PFOA treated rats at all time points. Liver adenomas were induced in 13% of the 
PFOA treated group versus 3% of the control group.  Leydig cell adenoma was induced 
in 11% of the testes of the PFOA treated group versus 0% of the control group with 
Leydig cell hyperplasia present in 46% of the animals exposed to PFOA in their diet.  
Acinar cell adenoma was induced in 9% of the PFOA treated animals versus 0% of the 
control group. The frequency of tumor induction is summarized in Table 2.4.  
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Table 2.4 
Summary of the Tumor Induction Frequency of APFO in Rats   
 
Blood was sampled at 1, 3, 6, 9, 12, 15, 18, and 21 months. Testosterone, follicle-
stimulating hormone (FSH), luteinizing hormone (LH), prolactin and estradiol levels 
were quantified in the serum from each of these samples with no significant differences 
found in serum testosterone, FSH, prolactin, or LH concentrations in the PFOA treated 
rats when compared to their controls. However, significant increases in serum estradiol 
concentrations were present in the PFOA treated rats at all months sampled compared to 
the control groups. 
 
Tumor Induced 
Incidence   
Control Rats    
(0 ppm APFO)
Frequency 
Control Rats    
(0 ppm 
APFO) 
Incidence 
Treated Rats     
(300 ppm 
APFO) 
Frequency  
Treated Rats     
(300 ppm 
APFO) 
Liver 
Adenoma 2/80 3% 10/76 13% 
Carcinoma 0/80 NONE 0/76 NONE 
Adenoma/carcinoma 
combined 2/80 3% 10/76 13% 
Testes 
Leydig cell 
hyperplasia 11/80 14% 35/76 46% 
Leydig cell 
adenoma 0/80 NONE 8/76 11% 
Pancreas 
Acinar cell 
hyperplasia 14/80 18% 30/76 39% 
Acinar cell adenoma 0/80 NONE 7/76 9% 
Acinar cell 
carcinoma 0/80 NONE 1/76 1% 
Adenoma/carcinoma 
combined 0/80 NONE 8/76 11% 
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III. MECHANISMS OF CARCINOGENICITY 
 
A.  Liver 
The available published scientific literature provides data suggesting that 
induction of hepatocellular adenomas by PFOA may result from: (1) generation of 
reactive oxygen species, (2) increased mitochondrial biogenesis, (3) the activation of 
Peroxisome Proliferator-Activated Receptor Alpha (PPARα),  (4) influence on molecular 
pathways such as those mediated by the constitutive androstane receptor (CAR), (5) the 
inhibition of gap junctional intracellular communication (GJIC), (6) increased estrogen 
levels and (7) modulation of the immune system. Data in support of these proposed 
mechanisms are described in the sections that follow.  
 
1)  Reactive Oxygen Species 
Chemically induced carcinogenesis is thought to consist of a multistage process 
definable by at least three steps or stages: initiation, promotion, and progression.  The 
oxidative stress that results from the presence of ROS impacts all three stages of the 
cancer process. During the initiation stage oxidative DNA damage may produce gene 
mutations and structural alterations of the DNA, resulting in a heritable mutation. During 
the promotion stage ROS and oxidative stress can contribute to abnormal gene expression 
and inhibition of GJIC which results in an increase in cell proliferation or a decrease in 
apoptosis in the initiated cell population. Oxidative stress may also participate in the 
progression stage of the cancer process by imparting further DNA alterations to the 
initiated cell population. These changes may result in changes in enzyme activity and 
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make the lesions resistant to normal growth control [61].  This is exemplified in figure 
3.1 taken from Klaunig et al. [61].  
 
Figure 3.1  
Summary of the roles of oxidative stress in carcinogenesis 
In a study by Liu et al. [62] cultured freshwater tilapia (Oreochromis niloticus) 
hepatocytes were exposed to PFOS or PFOA (at doses of 0, 1, 5, 15 and 30 mg/L for 24h) 
which resulted in a significant induction of reactive oxygen species (ROS) accompanied 
by increases in activities of superoxide dismutase (SOD), catalase (CAT) and glutathione 
reductase (GR), demonstrating that PFOA produced oxidative stress and induced 
apoptosis with involvement of caspases in primary cultured tilapia hepatocytes.  
Panaretakis et al. [63] measured reactive oxygen species (ROS) generation at 1.5, 3, 5 
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and 24 h after cultures of human HepG2 hepatoma cell lines were exposed to PFOA 
concentrations of 200 mM and 400 mM. At 3 h, 200 mM of PFOA had elicited detectable 
levels of H2O2 in 91% of the total cell population compared to 12% of the vehicle-treated 
cells and 400 mM PFOA induced H2O2 generation in 98% of the total cell population at 
the same time point.  Superoxide anions, which are another example of ROS species, 
reached detectable levels in 43% and 71% of the total cell population after treatment with 
200 mM and 400 mM PFOA respectively (versus 10% in DMSO-treated cells).  This 
accumulation of ROS is thought to be the result of disruption of the mitochondrial 
membrane. 
A study by Yao et al. [56] investigated the genotoxic potential of PFOA in human 
hepatoma HepG2 cells in culture using single cell gel electrophoresis (SCGE) assay and 
micronucleus assay.  Dichlorofluorescein diacetate was used as a fluorochrome to 
measure the intracellular generation of ROS with the level of oxidative DNA damage 
being evaluated by immunocytochemical analysis of 8-hydroxydeoxyguanosine (8-
OHdG) in PFOA-treated HepG2 cells. This study found significantly increased levels of 
ROS and 8-OHdG in the PFOA exposed cells which indicate that human HepG2 cells 
exposed to PFOA do produce ROS which may play a role in all three stages of the 
carcinogenesis process. 
 
2)  Mitochondrial Biogenesis 
PFOA does produce hepatic peroxisome proliferation (PP) in rats, which is 
discussed later; however, PFOA has been shown to stimulate mitochondrial biogenesis, 
which is not a characteristic response of PPs [64].  Berthiaume exposed male Spraque-
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Dawley rats to 100 mg/kg of the PP chemicals PFOA, PFOS and N-ethyl 
perfluorooctanesulfonamido ethanol dissolved in dimethyl sulfoxide (DMSO) via a single 
i.p. injection.  The animals were sacrificed 3 days post injection with the liver tissue and 
mitochondria collected from animals in each treatment group used to examine the effects 
of each compound on cytochrome oxidase activity, cytochrome content, and 
mitochondrial DNA copy number to determine their effect on mitochondrial biogenesis.  
PFOA and PFOS were capable of inducing PP in rats following injection; however, 
PFOA was the only compound that caused significant decreases in mitochondrial 
cytochrome oxidase activity with a significant increase in mitochondrial DNA copy 
number which reveals that a unique mitochondrial biogenesis is occurring in PFOA 
exposed rats that is not generally produced by other PPs.   
Starkov et al. [65] also demonstrated that PFOA and PFOS caused a slight 
increase in the intrinsic proton leak of the mitochondrial inner membrane, which 
resembled a surfactant-like change in membrane fluidity.   Since mitochondria play a 
significant role in cell signaling, ROS generation and apoptosis the resulting 
mitochondrial biogenesis seen in rodents exposed to PFOA may play a role in 
carcinogenesis. 
 
3)  PPARα Agonism 
 
PPARs are steroid hormone receptors that act as ligand-activated transcription 
factors.  Three PPAR isotypes have been identified, PPAR α, β/δ and γ.  These isotypes 
play a role in lipid metabolism, energy homeostasis and inflammation [66].  PPAR 
agonism results in an increase in the number and volume fraction of peroxisomes in the 
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cytoplasm of cells.  This proliferation can be visualized utilizing electron microscopy or 
can be quantitated by measuring the levels of selected peroxisome enzymes such as 
catalase, cytochrome P-450s (e.g., CYP4A1and 4A3), and acyl coenzyme A (CoA) 
oxidase.  The response to exposure to PP chemicals, such as PFOA, varies drastically 
between species with the rat and mouse being the most sensitive.   PP has been shown to 
be present in the hamster, to a lesser degree than the rat and mouse, with relatively no PP 
present in the guinea pig, monkey, and human when exposed to PPAR agonists at dose 
levels that produce marked response in the rat and mouse [67-70]. The liver tumors 
induced by PFOA exposure in rodents appears to occur as a result of PFOA binding to 
the PPARα, which results in PP [60, 71, 72]. PFOA is believed to produce these tumors 
in the liver by binding with and, as a result, activating PPARα.  PPARα modulates the 
transcription of genes involved in PP, regulation of the life/death cycle of the cell and 
lipid metabolism.  PPARα activation produces a proliferation of the peroxisomes, an 
increase in cell proliferation and a decrease in apoptosis.  The decrease in cell death 
combined with increased stimulation in cell proliferation results in increased cell 
reproduction.  This reproduction promoting environment coupled with the presence of 
ROS, and their resultant oxidative stress, promotes the reproduction of DNA-damaged 
cells. As a result preneoplastic foci arise and in the course of time develop into tumors by 
way of continued clonal expansion [73]. 
 
4)  CAR Activation 
PFOA has also been shown to activate CAR.  CAR activation is essential in liver 
tumor promotion by other nongenotoxic liver carcinogens such as Phenobarbital (PB) 
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[74]. A DNA microarray analysis of hepatic gene expression in Car–/– mice showed that 
CAR induced or repressed 70 genes [75].  In addition to up-regulation of drug-
metabolizing enzymes, CAR down-regulated genes that encode gluconeogenic enzymes, 
those involved in fatty acid oxidation, and proteins such as angiogenin and fibronectin.  
Nongenotoxic carcinogens such as PB are known to stimulate cell proliferation and 
suppress apoptosis, leading to tumor development. While PFOA has been shown to 
activate PPARα [71], PFOA also produces liver enlargement in the PPARα-null knock-
out mice [76, 77]. This PPARα-independent effect suggests other mechanism of 
carcinogenicity may be present other than PPARα activation. A study of gene expression 
changes in PPARα-null mice exposed to PFOA revealed an up-regulation of certain 
Cyp2b and Cyp2c genes, such as Cyp2b10, which are markers of CAR activation [78-
80].  Another study revealed that two days after a single i.p. administration (50 mg/kg) of 
(PFOA) and perfluorodecanoic acid (PFDA), mRNA expression of Cyp2b10 was 
increased 20-fold [81].  It was also shown that there is a strong correlation between the 
transcript profile of PPARα independent PFOA genes in PPARα-null mice exposed to 
PFOA and those of activators of CAR including Phenobarbital [82] which would suggest 
that a subset of genes are controlled by CAR in the PPARα-null mouse exposed to 
PFOA. 
 
5)  GJIC Inhibition 
When normal cells are no longer able to control their growth by way of contact 
inhibition, they can become transformed into tumorigenic cells [83] which may be due to 
defective intercellular communication [84].  These transformed cells can be benign or 
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they can develop genetic mutations that lead to a malignant state as demonstrated in 
multistage carcinogenesis.   It has been implied that changes occurring in the cell-to-cell 
communication by way of gap junction does play a role in the tumorigenic process [85]. 
A recent study by Upham et al. [86] verified that PFOA does inhibit GJIC and induce 
hepatomegaly in the livers of rats while the measured level of liver enzymes indicated no 
cytotoxic response.  The inhibition of GJIC was shown to be dependent on the activation 
of both ERK and phosphatidylcholine-specific phospholipase C (PC-PLC) in the 
dysregulation of GJIC in an oxidative-dependent mechanism. This study also indicated 
that PFOA is able to activate the extracellular receptor kinase (ERK).   In a previous 
study, Upham et al. [87] demonstrated that PFOA reversibly inhibited GJIC and this 
inhibition of GJIC was dependent on the length of the fluorinated tail. Since GJIC plays 
an essential role in preserving tissue homeostasis, disruption of gap junction function 
may play a role in the carcinogenicity of PFOA. 
 
6)  Estrogenic Signaling 
It is known that PFOA can produce PP in rodents, however humans and certain 
other species, including rainbow trout, guinea pigs, and nonhuman primates, show little 
to no evidence of PP [70, 88, 89].  A study by Tilton et al. [90] of rainbow trout exposed 
to PFOA (1,800 ppm or 50 mg/kg/day) and DHEA demonstrated enhanced liver tumor 
incidence in trout exposed to PFOA at concentrations of 50 mg/kg per day.  This 
carcinogenic effect was independent of PP which was determined by a lack of 
peroxisomal β-oxidation and catalase activity.   Gene profiling also demonstrated that 
PFOA induced an estrogenic gene signature that strongly correlated with that produced 
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by 17β-estradiol.  The results from this study suggest that the tumor-promoting activities 
of PFOA in trout are independent of PP and instead may be related to a mechanism 
involving estrogenic signaling.  A study by Liu et al. [91] demonstrated that PFOA 
possesses estrogenic activities and additional results of an estrogen receptor inhibition 
assay indicated that the estrogenic effect of PFCs may be mediated by the estrogen 
receptor pathway in primary cultured tilapia hepatocytes.  A gene expression profile 
study was conducting using liver tissue obtained from male and female rare minnows 
(Gobiocypris rarus) exposed to PFOA using a custom cDNA microarray containing 1773 
unique genes by Wei et al. [92].  The minnows were treated with continuous flow-
through exposure to PFOA at concentrations of 3, 10, and 30 mg/L for 28 days. 
Hepatocyte swelling and vacuolar degeneration with prominent eosinophilic hyaline 
droplets were observed in the cytoplasm of male and female hepatocytes exposed to 10 
mg/L. The livers from the cohort exposed to 10 mg/L PFOA were selected for further 
hepatic gene expression analysis.  The results revealed that a number of genes were either 
upregulated or downregulated in the livers of the minnows exposed to PFOA with a 
distinct induction of estrogen-responsive genes identified using a custom cDNA 
microarray.  The fact that other studies [93, 94] have shown that estrogen promotes liver 
carcinogenesis in rats makes the estrogenic signaling properties of PFOA a viable 
pathway for tumor promotion in the liver.   
 
7)  Immunomodulation 
A healthy and fully functional immune response allows the body to identify and 
remove abnormal cells, including initiated cells, while a weakened or suppressed immune 
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system has been associated with increased tumor development [95-97].  A study by Yang 
et al. [98] demonstrated that exposure of Male C57B1/6 mice to PFOA in the diet 
resulted in severe thymic and splenic atrophy with the weight of the thymus and spleen 
rapidly returning to normal within 10 and 5 days, respectively, following withdrawal of 
PFOA from the diet.  It was also noted that these changes in thymus and spleen weight 
paralleled the changes in total thymocyte and splenocyte counts.  Yang also evaluated the 
effects of PFOA on the adaptive immunity in mice by measuring antigen-specific 
antibody responses and lymphocyte proliferation in mice immunized with horse red 
blood cells [77].  Mice were fed a diet of 30 mg PFOA/kg for 15 days after which the 
immune response was quantified by employing both the plaque-forming cell assay and 
determination of the antibody titer by ELISA.  The results of the study revealed a 
suppression of the IgM and IgG titers relative to the titers present in the unexposed 
control animals and reduced plaque formations in the exposed animals compared to the 
animals in the control group.   The results from another study by Yang [99] revealed that 
while PFOA treatment of wild type mice led to a dramatic atrophy of the thymus and 
spleen reflecting losses of thymocytes and splenocytes, this effect is not as dramatic in 
PPARα-null mice.  Although the atrophy of the thymus and loss of thymocytes was not 
as marked as in the wild type mice, significant thymus atrophy and loss of thymocytes 
were observed in PPARα-null mice exposed to PFOA.  This weakened response clearly 
points toward the involvement of both PPARα-dependent and -independent mechanisms 
in the immunomodulation process.  Note that although immunomodulation is only 
discussed in this section the immune response is a physiological response of the body and 
modulation of the immune system affects the body as a whole.  As a result the 
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immunomodulation by PFOA may play a plausible role in tumorigenesis in the liver, 
testis and pancreas.   
 
B.  Testis 
Leydig cell adenomas are another type of tumor that is produced by exposure to 
PFOA.  The available published scientific literature provides data suggesting that 
induction of Leydig Cell adenomas by PFOA may result from: (1) inhibition of 
testosterone biosynthesis and (2) estradiol modulation.   Data in support of these 
proposed mechanisms are described in the sections that follow.  
 
1)  Inhibition of Testosterone Biosynthesis 
 
Inhibition of testosterone biosynthesis may be involved in the induction of Leydig 
cell tumors by PFOA which has been shown to decrease the production of testosterone in 
Leydig cells that are exposed to the compound [100].  Results from a study by Gazouli et 
al. [101] indicate that the inhibition of testosterone production may also be mediated by 
PPARα.  Decreased testosterone levels can lead to increased luteinizing hormone levels 
through a negative feedback mechanism called the hypothalamic pituitary testicular 
(HPT) axis that regulates metabolism. The disruption of the hypothalamus pituitary 
thyroid axis in the thyroid gland has been shown to produce follicular cell carcinoma in 
the thyroid [102] and may be applicable to LCT formation in the testis as a disruption of 
the HPT axis.  Several studies have produced sustained hypersecretion of LH in the testis, 
which are compromised of endocrine controlled tissues, with the disruption of the HPT 
axis [103-109].  This mechanism was demonstrated in a 1-year study where Viguier-
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Martinez et al. [108, 109] fed Sprague-Dawley rats feed containing flutamide, which is an 
androgen receptor antagonist that blocks the binding of testosterone to the testosterone 
receptor and results in hypersecretion of LH due to the disruption of the HPT axis, and 
produced Leydig cell hyperplasia in the animals fed flutamide which progressed to 
Leydig cell adenoma by the end of the study. 
 
2)  Estradiol Modulation 
Since PP chemicals have been shown to increase estradiol levels and estradiol 
modulates growth factor expression in the testes then PFOA may produce Leydig cell 
tumors (LCT) in the testes as a result of the increased cell hyperplasia produced by 
estradiol [100, 110].  Administration of estradiol to mice has produced Leydig cell 
tumors in several studies [111-113] which further supports the plausibility that PFOA can 
produce these tumors due to the compounds ability to increase estradiol levels.  It is also 
plausible that elevated estradiol levels may act as a mitogen and/or enhance growth factor 
secretion thereby causing Leydig cell hyperplasia and tumor formation.  The 
transforming growth factor α has been detected in Leydig cells[114] which stimulates cell 
proliferation and is an example of how enhanced growth factors could be involved in 
tumor formation. 
Although peroxisomes are present in both the liver and testes the limited data on 
Leydig cell induction by PFOA does not support PP as a plausible MOAs for tumor 
production in the testes.  Two separate studies exposing male rats to known PP chemicals 
found abundant PP in the liver using biochemical assays and visual examination with 
electron microscopy with no PP found in the Leydig cells [115, 116].  Currently no other 
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data exists to support any other alternate MOAs for LCT formation other than the 
hormonal mechanisms described.   
 
C.  Pancreas  
Pancreatic acinar cell tumors (PACT) are a third tumor type produced by 
exposure to PFOA.  The available published scientific literature provides data suggesting 
that induction of pancreatic tumors by PFOA may result from cholestasis. 
 
1)  Hepatic Cholestasis 
Steroids (such as estradiol and testosterone discussed previously), 
cholestcystokinin (CCK) and other growth factors, growth factor receptor over-
expression (CCKA receptor) and dietary fat intake have all been shown to produce PACTs 
in rats when their levels are altered [117-119].   PACT induction by PFOA and other PP 
appears to be seen in rats, but not mice, which indicates that PACT tumor formation may 
be species dependant [67, 68].  A chronic study by Osbourn et al. [120] demonstrated 
increases in pancreatic weights at 3 months (6% above control) and 6 months (17% above 
control) with an increase in CCK plasma levels in a 2 year bioassay of rats exposed to the 
PP chemical WY.  The results of the study indicate that chronic exposure to WY causes 
liver alterations such as cholestasis, which may increase plasma concentrations of CCK.  
PP chemicals such as PFOA may thus induce PACT as a result of a sustained mild 
increase in CCK levels produced by hepatic cholestasis.  Results from a second study by 
Osbourn et al. supported the validity of the role of increased CCK levels in PACT 
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formation [121].  The diagram below (Figure 3.2) depicts the proposed mode of action 
(MOA) with key events for pancreatic acinar cell tumors (PACTs) induced by PFOA.  
 
Figure 3.2 
Illustration detailing the proposed MOA for PFOA pancreatic acinar cell tumorigenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
As described above, the experimental evidence suggests that PPARα agonists 
such as PFOA induce PACTs in rats by increasing CCK levels secondary to reduced bile 
acid synthesis and/or alterations in bile acid composition [120, 121].  PPARα agonists 
have been shown to decrease transcription of cholesterol 7α-hydroxylase, the rate-
limiting step of bile acid synthesis, via the PPARα/RXRα heterodimer reducing 
hepatocyte nuclear factor-4 (HNF-4) binding to the DR-1 sequence, which regulates this 
gene [122]. The inhibition of cholesterol 7α-hydroxylase results in reduced bile flow and 
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altered bile acid composition resulting in cholestasis.  This reduction in bile acid flow 
and/or altered bile acid composition creates a reduction in trypsin activity which 
increases the CCK release from the duodenal mucosa.  This increased release of CCK 
results in increased activation of the CCKA receptors which can increase acinar cell 
proliferation and may lead to tumor formation. 
The mechanisms of carcinogenicity by PFOA that have been detailed are 
summarized in Figure 3.3. 
 
Figure 3.3 
Summary of Possible Mechanisms for PFOA Carcinogenicity in Rodents 
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IV. HUMAN RELEVANCE 
 
As described in the MECHANISMS OF CARCINOGENICITY section, PFOA 
has been shown to produce cancer in laboratory animals. This section previews studies 
that have used human sources in an attempt to determine if the possible mechanisms of 
carcinogenicity hypothesized in animal models are applicable to human risk.  
 
A.  Liver 
The induction of hepatocellular adenomas by PFOA in rodents may involve any 
of several pathways including ROS, CAR, GJIC, increased estrogen levels, decreased 
immune system response and/or PPARα agonism. Many of these pathways are plausible 
in human carcinogenesis. 
 
1)  ROS Generation 
Results of a recent study established that PFOA produces genotoxic effects on  
human HepG2 cells [56].  This DNA damage is thought to be the result of oxidative 
stress induced by intracellular ROS, particularly hydrogen peroxide.  In this study the 
fluorochrome 2’,7’-dichlorofluorescin was used to measure intracellular generation of 
ROS and 8-OHdG was used to determine the level of oxidative DNA damage.  A 
separate study by Hu et al. [123] that exposed human Hep G2 cells to PFOA and PFOS at 
concentrations of 50-200 μmol/l  (50–200 μmol/l) resulted in the generation of ROS.  
Panaretakas et al. [63] also demonstrated that human Hep G2 cells treated with 200 and 
400 umol PFOA exhibited a dramatic increase in the cellular content of superoxide 
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anions and hydrogen peroxide after 3 h.  Hypolipidemic drugs, which are known PP, 
were also shown to induce an overproduction of ROS in human hepatocytes [124].  Many 
other studies have implicated ROS and oxidative stress in human liver tumors [125-129] 
which indicates that ROS generation by PFOA may play a role in human carcinogenesis 
and warrants further study.   
 
2)  CAR Activation 
As previously discussed, PPARα-null mice exposed to PFOA developed liver 
enlargement and a measurable up-regulation of Cyp2b and Cyp2c genes, which are 
markers of CAR activation.   PB is known to stimulate cell proliferation and suppress 
apoptosis, leading to tumor development via the CAR activation pathway but has 
typically not been shown to produce liver tumors in humans [130].  Although little 
evidence suggests that CAR activation by PFOA could result in tumor formation in the 
liver, CAR expression shows a large amount of genetic polymorphism as demonstrated in 
a study by Change et al. [131] that revealed a 240-fold variability in hepatic CAR mRNA 
levels in humans.  This highly variable expression among individuals may explain why 
there are reported cases of liver tumors in humans that have been on long term PB 
therapy [132, 133] and could represent a plausible tumorigenic pathway for a subset of 
the human population that highly express CAR and are exposed to high levels of PFOA. 
 
3)  GJIC Inhibition 
Since carcinogenesis involves a disturbance of homeostasis and cancer cells show 
uncontrolled growth, it is conceivable that altered GJIC plays an important role in 
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carcinogenesis.   PFOA has been shown to inhibit GJIC and induced hepatomegaly in rat 
livers [86].  As previously discussed the inhibition of GJIC in rats appears to depend on 
the activation of the ERK pathway.  In studies of human cancer cell lines GJIC was 
absent or decreased in all human cancer cell lines that were analyzed by Mesnil et al. 
[134] and was found to be decreased in human hepatocellular carcinoma tissues and cell 
lines by other investigators as well [135-137]. The inhibition of GJIC via ERK activation 
has been shown to be a key pathway of in human carcinogenesis [138].  The potential for 
cross-species effects of PFOA on GJIC was established in a study by Hu et al. where 
PFOS was shown to inhibit GJIC in rat liver tissue as well as dolphin kidney cells [139].   
The ability of perfluorinated chemicals to inhibit GJIC appears to be neither species- nor 
tissue-specific and can occur both in vitro and in vivo.  Currently studies evaluating GJIC 
inhibition by PFOA in human cell lines are lacking.  Future experiments, particularly 
with human cell lines, on the inhibitory effect of perfluorinated chemicals on GJIC are 
needed as this may be a plausible MOA for carcinogenesis in humans. 
 
4)  Estrogenic Signaling 
Although it was discussed previously that PFOA has been shown to promote liver 
tumors in fish that lack PPARα through disruptions in estrogenic signaling, more studies 
are needed to assess the potential for PFOA to mediate carcinogenesis through the 
estrogenic pathway in other species such as humans. A previous study in primates [140] 
did not find any evidence of PFOA increasing estrogen levels which would infer that the 
estrogenic pathway would not be likely involved in human hepatocarcinogenesis, 
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however studies involving human cell lines are needed to exclude estrogenic signaling as 
a plausible MOA for PFOA carcinogenesis in humans. 
 
5)  Immunomodulation 
As discussed previously PFOA and other PP chemicals do exert an effect on the 
immune system of study animals.  The mechanisms are not clear as to why these 
chemicals are able to modulate the immune system and more research is needed to 
determine the impact on the human immune system as there does appear to be 
considerable species variability in the degree of response. The fact that the 
immunomodulatory effects of PFOA can be present independent of PPARα activation 
would imply that it would be possible for PFOA to induce liver carcinogenesis in humans 
via these effects as well as in other tissues and warrants further investigation.  
 
6)  PPARα Agonism 
PFOA has been shown to act as a strong tumor promoter in rodent livers [141] as 
well as other PP chemicals [142].  The PP produced by PFOA, which is thought to be the 
result of PFOA binding to the PPARα, does not appear to be occur in human livers, as 
humans show little [140] to no evidence of PP.  This may be due to the lower PPARα 
expression found in humans compared to rodents as reported by Palmer et al. [143] who 
found a >10-fold lower PPARα DNA binding activity in human liver lysates than the 
levels found in mouse liver lysates.   There is also evidence that activation of the human 
PPARα receptor elicits a different response than activation of the mouse PPARα receptor.  
This has been demonstrated in studies using a PPARα humanized mouse in which 
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PPARα-null mice have been genetically manipulated to express human PPARα at levels 
comparable to the mouse PPARα found in wild-type mice. In these studies fibrates 
altered the expression of genes associated with lipid metabolism in both wild-type and 
PPARα-humanized mice, however these compounds did not induce the hepatocyte 
proliferation in the PPARα-humanized mouse that is observed in the wild-type mice nor 
did the compounds induce the liver tumor formation in the PPARα-humanized that is 
observed in wild-type mice.  This information reinforces the theory that the effects of 
peroxisome proliferators are species specific and the induction of liver tumors by PFOA 
due to PPARα activation is highly unlikely [73].                                                                                           
 
B.  Testis 
It has been shown that PFOA does exert an effect on human testicular function as 
evident in a study by Joensen et al. [144] that analyzed serum samples for levels of 10 
different PFAAs and reproductive hormones and assessed semen quality in 105 Danish 
men from the general population (median age, 19 years).  They discovered the presence 
of measurable quantities of PFOS and PFOA in all subjects with a median of 24.5 and 4.9 
ng/mL respectively. A significant decrease in semen production was found in men with 
high combined levels of PFOS and PFOA compared to those with low levels.  Men 
exposed to high combined levels of PFOS and PFOA were found to produce 6.2 million 
normal spermatozoa in their ejaculate in contrast to 15.5 million among men with low 
levels of these PP chemicals in their bloodstream.  Not only is it apparent that PFOA 
exerts an effect on testicular function but it is also plausible that the estradiol modulation 
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MOA for LCT formation seen in the rat exposed to PFOA may also be relevant in 
humans. 
   
1)  Estradiol Modulation 
The ability of PFOA to induce human LCTs via the MOA associated with 
increased serum estradiol and testicular growth factors discussed previously in rodents 
may be of relevance to humans.  Several authors have reported that estrogen receptor 
(ER) expression is present in the normal LCs of human adult testis [145-147] which 
indicates that these cells are a target for estrogens.  It has also been shown that the 
cytochrome P450 aromatase, an enzyme that catalyzes the androgen aromatization into 
estrogens, has been detected in Leydig cells of normal human testis [148], which further 
suggests that locally produced estrogens plays a role in steroid production and 
spermatogenesis [149].  A recent human study by Carpino et al. [150]  investigated the 
expression of aromatase and estrogen receptors (ER, ERβ1, ERβ2) in testes from two 
patients with LCTs. A strong immunoreactivity for aromatase, ERβ1, and ERβ2, together 
with a detectable ER immunostaining, was revealed in tumoral tissues. These findings 
were confirmed by Western blot analysis of tumor extracts. The pattern of ER expression 
in the LCT cells was also demonstrated to be different from that of control Leydig cells 
which exhibited only ERβ1 and ERβ2 isoforms. The results of this study reveals that it is 
plausible that high estrogen production could play a role in the neoplastic transformation 
of Leydig cells and the exclusive presence of ER in tumoral cells could amplify estradiol-
17β signaling contributing to the tumor cell growth and progression produced by PFOA. 
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C.  Pancreas  
The tumorigenic pathways of PACT induction by PFOA in rodents that was 
discussed previously in this review may not be relevant in humans as the expression of 
CCKA  receptors in humans are much lower than rodents with data indicating that human 
pancreatic acinar cells do not respond to CCK receptor activation due to an insufficient 
level of receptor expression [151].  A study of cynomolgus monkeys exposed to PFOA 
for 6-months did not produce any effects on CCK levels or evidence of cholestasis [140] 
and human epidemiological studies of CCK levels in employees exposed to high levels of 
PFOA did not reveal any increases of CCK levels in workers [152, 153].  These studies 
also imply a lack of CCK receptor expression in humans.  It is also important to note that 
the majority of human pancreatic cancers are of the ductal type and are not derived from 
the acinar cells [154] as found in the PACT that is produced in rodents exposed to PFOA.  
With the incidence of pancreatic cancer in humans increasing every year, it has now 
become the fourth leading cause of cancer deaths [155], the ability of PFOA to induce 
pancreatic tumors in humans may warrant further investigation as the exact mechanism of 
PFOA carcinogenesis is not known, however the PACT induced in the rat would 
probably not correspond to a significant cancer risk in humans.   
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V.  EPIDEMIOLOGICAL STUDIES 
 
The current epidemiological studies of the carcinogenic effects of human 
exposure to PFOA are inconclusive.  The current data is based on occupational studies 
most of which was conducted by the 3M company on male workers from their plants.  In 
a 3M mortality study, prostate cancer mortality was the only statistically significant 
association found for workers exposed to high levels of PFOA in the manufacturing 
process; however, this was not observed in follow-up studies that utilized more specific 
exposure measures [156, 157].  A DuPont study did reveal an increase in the incidence of 
kidney and bladder cancer [158], but this study included very little data on other variables 
such as exposure to other chemicals in the plant.  An epidemiological study by Olsen et 
al. [153] looking at hormone levels in exposed workers found estradiol to be the only 
hormone level increased in workers exposed to PFOA and this increase was found only in 
workers with the highest levels of PFOA in their serum.  As discussed in the pancreatic 
section previously, an epidemiological study was done on CCK levels in employees 
exposed to PFOA with no increase in pancreatic tumor formation found [152, 153].  
There is a pertinent need for collection and analysis of more human data regarding PFOA 
exposure as there is currently little epidemiological data available, most of which has 
been collected and analyzed by the industry that manufactures PFOA. 
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VI. DISCUSSION AND SUMMARY 
 
As previously discussed PFOA, can be detected in the entire population of the 
United States.  The EPA Science Advisory Board has reviewed the information that was 
available at the time, and suggested that the PFOA cancer data are consistent with the 
EPA Guidelines for Carcinogen Risk Assessment descriptor “likely to be carcinogenic to 
humans.”  On January 9, 2009, EPA’s Office of Water developed Provisional Health 
Advisories (PHA) for PFOA and PFOS to protect against potential risk from exposure to 
these chemicals through drinking water. Provisional Health Advisories serve as informal 
technical guidance to assist federal, state and local officials in response to an urgent or 
rapidly developing drinking water contamination. They reflect reasonable, health-based 
hazard concentrations above which action should be taken to reduce exposure to these 
contaminants in drinking water. The PHA values are 0.4 µg/L for PFOA and 0.2 µg/L for 
PFOS.  It is striking to note that the PHA value for PFOA in drinking water is 0.4 µg/L 
when the mean serum concentration in the US population was found to be 3.9 µg/L in 
2003-2004 [7] and 3.4 µg/L in 2006 [7, 159].  The EPA and the eight major companies in 
the industry launched the PFOA Stewardship Program in 2006, in which companies 
committed to reduce global facility emissions and product content of PFOA and related 
chemicals by 95 percent by 2010 and to work toward eliminating emissions and product 
content by 2015.  It is evident that the EPA and manufacturers of PFOA are in agreement 
that PFOA is a persistent environmental contaminant that poses a potential health risk to 
the human population.   
The pathways by which the tumor triad is produced by PFOA exposure in rodents 
is still not clear.  It is evident that PPAR agonism plays a role in liver adenomas yet the 
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MOA for tumor production in the rodent testes and pancreas is still unknown.  Although 
current data supports that the PPAR agonistic properties of PFOA may not be applicable 
to human risk, since humans show little PP, several additional rodent tumorigenic 
pathways presented in this thesis may be applicable to humans.  Current research 
supports that exposure to PFOA results in the generation of ROS in humans and ROS and 
oxidative stress have been shown to play a role in tumor production in humans.  PFOA 
has been shown to interfere with GJIC by inhibiting GJIC via the ERK pathway which 
has been shown to be a key pathway of carcinogenesis in humans.  The alteration of the 
immune system by PFOA appears to result in a weakened immune system.  A weakened 
or suppressed immune system has been associated with increased tumor development.  
Increased estradiol levels were found in an epidemiologic study by Olsen described 
previously in this thesis and PP chemicals such as PFOA have been shown to increase 
estradiol levels.  This modulation of estradiol has been demonstrated to play a role in LC 
tumor formation in humans. The activation of the CAR pathway by PFOA has also been 
discussed in this thesis and a subset of the human population that highly express CAR 
may be susceptible to tumor formation as a result of CAR activation by PFOA. It is 
conceivable that each of these pathways may represent pathways of PFOA carcinogenesis 
in humans.   
The global presence and environmental persistence of PFOA, combined with the 
long half life of PFOA in  humans (4.37 years [160]), warrants careful consideration as to 
the proper handling, use and disposal of this chemical.  With little epidemiological 
studies conducted, most of which have been performed by industries that manufacture 
PFOA,  and given that PFOA is accumulating in not only the occupationally exposed, but 
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also in the general population is of concern.  The ubiquitous presence of PFOA in the 
environment compounded with the possibility that viable carcinogenic pathways exist in 
experimental animals that are mirrored in human carcinogenesis reflect a need to further 
evaluate the carcinogenic potential of PFOA in humans and the need for continued 
epidemiological studies of the human population. 
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